stockrow
Friday 6 November 2026
Export CNXU’s income statement to Excel — free account
Conexeu Sciences Inc.
CNXU Healthcare Biotechnology
- EPS
- −214.9%
- Free cash flow
- −1,084.3%
Quarter to July 2026, against a year earlier
2.09
0.13
−5.86%
Follow CNXU
Alert me
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Older periods | |
|---|---|---|---|---|---|
| (458.40%) | 0.00% | 0.00% | 0.00% |
+4 more TTM periods Free account |
|
| (354.37%) | (175.58%) | (138.97%) | (95.44%) | ||
ROIC |
(234.60%) | 0.00% | (2,853.99%) | (98.33%) | |
Return on Tangible Assets |
(245.15%) | (96.99%) | (75.74%) | (55.00%) | |
Average Days of Receivables |
0.00 | 0.00 | — | 0.00 | |
Free Cash Flow per Share |
(0.39) | (0.21) | (0.15) | (0.13) | |
Free Cash Flow |
(10.61) | (4.38) | (2.98) | (1.69) | |
Capital Expenditures |
(0.08) | (0.04) | (0.01) | (0.02) | |
| Other line items | |||||
Cash ROIC |
(131.60%) | (30.22%) | (22.02%) | (13.86%) | |
Accounts Payable Turnover |
0.00 | — | — | — | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | — | — | (808.63) | |
Operating CF/Net income |
0.77 | 0.60 | 0.56 | 0.43 | |
Depreciation/Fixed assets |
0.40 | 0.81 | 2.08 | 1.54 | |
Capex/Depreciation |
(2.54) | (1.13) | (0.43) | (1.08) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.39) | (0.21) | (0.15) | (0.13) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026